CTLA4 and cancer: The advent of immune checkpoint inhibitors, such as antibodies that target cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and programmed death 1/programmed death-ligand 1 (PD-1/PD-L1), has redefined cancer immunotherapy, and these inhibitors have rapidly become an emerging pillar of cancer treatment [6].